FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

Why it matters locally: This FDA approval is significant for California given the state's diverse population, where sickle cell disease and beta-thalassemia may be more prevalent in certain communities. Access to this new treatment could directly impact families and healthcare providers within the state.

The U.S. Food and Drug Administration (FDA) today announced a supplemental approval for Casgevy (exagamglogene autotemcel). This expanded approval permits the use of the gene therapy for patients aged two years and older. The therapy is indicated for individuals diagnosed with sickle cell disease (SCD) who experience recurrent vaso-occlusive crises (VOCs). Additionally, the approval covers patients with transfusion-dependent beta thalassemia (TDT).